Sorafenib induces autophagy in human myeloid dendritic cells and prolongs survival of skin allografts

Jiunn Chang Lin, Wei Pang Huang, Chien Liang Liu, Jie Jen Lee, Tsang Pai Liu, Wen Chin Ko, Yu Chuen Huang, Ming Ling Hsu, Chih Hsiung Wu, Yu Jen Chen

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background. Sorafenib, a multikinase inhibitor approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, has been reported inhibitory on the function of dendritic cells. This study was aimed to determine the effects of sorafenib on inducing autophagy and immunomodulatory activity and its implication on graft rejection. Methods. Cell viability and surface antigens were examined by 7-amino-actinomycin D and flow cytometric analysis. Autophagy was characterized using light microscopy and transmission electron microscopy for morphology, Western blotting for LC3B-I lipidation and mammalian target of rapamycin signaling molecules, and immunofluorescence staining for endogenous LC3B, GFP-LC3 transfection, and acidic component vacuoles. Skin allograft in mice was used as an experimental transplantation rejection model. Soluble factors contained in culture medium and serum were measured by enzyme-linked immunosorbent assay. Results. We found that sorafenib inhibited the viability of dendritic cells accompanied by morphologic changes characteristic of autophagy and immature differentiation. This autophagic effect induced by sorafenib was validated by LC3B-I lipidation and autophagosome accumulation. Sorafenib treatment was associated with the down-regulation of phosphorylated mammalian target of rapamycin and its downstream substrate p70S6K. We next performed skin graft model to testify the role of sorafenib-induced immature and autophagic dendritic cells. Intriguingly, sorafenib prolonged the survival of skin allograft without major toxicity. Blockade of autophagic flux by chloroquine partially diminished the protective effect of sorafenib, indicating an autophagy-related mechanism in vivo. Conclusion. This study suggests that sorafenib, in addition to being an anticancer agent, may have potential to be developed as a new category of immunosuppressant drugs acting via autophagy induction of dendritic cells.

Original languageEnglish
Pages (from-to)791-800
Number of pages10
JournalTransplantation
Volume95
Issue number6
DOIs
Publication statusPublished - May 27 2013

Fingerprint

Autophagy
Myeloid Cells
Dendritic Cells
Allografts
Cell Survival
Skin
Graft Rejection
Sirolimus
70-kDa Ribosomal Protein S6 Kinases
sorafenib
Chloroquine
Surface Antigens
Immunosuppressive Agents
Vacuoles
Transmission Electron Microscopy
Renal Cell Carcinoma
Antineoplastic Agents
Fluorescent Antibody Technique
Transfection
Culture Media

Keywords

  • Allograft tolerance
  • Autophagy
  • Dendritic cell
  • mTOR
  • Sorafenib

ASJC Scopus subject areas

  • Transplantation

Cite this

Lin, J. C., Huang, W. P., Liu, C. L., Lee, J. J., Liu, T. P., Ko, W. C., ... Chen, Y. J. (2013). Sorafenib induces autophagy in human myeloid dendritic cells and prolongs survival of skin allografts. Transplantation, 95(6), 791-800. https://doi.org/10.1097/TP.0b013e31827fac48

Sorafenib induces autophagy in human myeloid dendritic cells and prolongs survival of skin allografts. / Lin, Jiunn Chang; Huang, Wei Pang; Liu, Chien Liang; Lee, Jie Jen; Liu, Tsang Pai; Ko, Wen Chin; Huang, Yu Chuen; Hsu, Ming Ling; Wu, Chih Hsiung; Chen, Yu Jen.

In: Transplantation, Vol. 95, No. 6, 27.05.2013, p. 791-800.

Research output: Contribution to journalArticle

Lin, JC, Huang, WP, Liu, CL, Lee, JJ, Liu, TP, Ko, WC, Huang, YC, Hsu, ML, Wu, CH & Chen, YJ 2013, 'Sorafenib induces autophagy in human myeloid dendritic cells and prolongs survival of skin allografts', Transplantation, vol. 95, no. 6, pp. 791-800. https://doi.org/10.1097/TP.0b013e31827fac48
Lin, Jiunn Chang ; Huang, Wei Pang ; Liu, Chien Liang ; Lee, Jie Jen ; Liu, Tsang Pai ; Ko, Wen Chin ; Huang, Yu Chuen ; Hsu, Ming Ling ; Wu, Chih Hsiung ; Chen, Yu Jen. / Sorafenib induces autophagy in human myeloid dendritic cells and prolongs survival of skin allografts. In: Transplantation. 2013 ; Vol. 95, No. 6. pp. 791-800.
@article{3754d4c837f0476a8866f3ba85eb12f3,
title = "Sorafenib induces autophagy in human myeloid dendritic cells and prolongs survival of skin allografts",
abstract = "Background. Sorafenib, a multikinase inhibitor approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, has been reported inhibitory on the function of dendritic cells. This study was aimed to determine the effects of sorafenib on inducing autophagy and immunomodulatory activity and its implication on graft rejection. Methods. Cell viability and surface antigens were examined by 7-amino-actinomycin D and flow cytometric analysis. Autophagy was characterized using light microscopy and transmission electron microscopy for morphology, Western blotting for LC3B-I lipidation and mammalian target of rapamycin signaling molecules, and immunofluorescence staining for endogenous LC3B, GFP-LC3 transfection, and acidic component vacuoles. Skin allograft in mice was used as an experimental transplantation rejection model. Soluble factors contained in culture medium and serum were measured by enzyme-linked immunosorbent assay. Results. We found that sorafenib inhibited the viability of dendritic cells accompanied by morphologic changes characteristic of autophagy and immature differentiation. This autophagic effect induced by sorafenib was validated by LC3B-I lipidation and autophagosome accumulation. Sorafenib treatment was associated with the down-regulation of phosphorylated mammalian target of rapamycin and its downstream substrate p70S6K. We next performed skin graft model to testify the role of sorafenib-induced immature and autophagic dendritic cells. Intriguingly, sorafenib prolonged the survival of skin allograft without major toxicity. Blockade of autophagic flux by chloroquine partially diminished the protective effect of sorafenib, indicating an autophagy-related mechanism in vivo. Conclusion. This study suggests that sorafenib, in addition to being an anticancer agent, may have potential to be developed as a new category of immunosuppressant drugs acting via autophagy induction of dendritic cells.",
keywords = "Allograft tolerance, Autophagy, Dendritic cell, mTOR, Sorafenib",
author = "Lin, {Jiunn Chang} and Huang, {Wei Pang} and Liu, {Chien Liang} and Lee, {Jie Jen} and Liu, {Tsang Pai} and Ko, {Wen Chin} and Huang, {Yu Chuen} and Hsu, {Ming Ling} and Wu, {Chih Hsiung} and Chen, {Yu Jen}",
year = "2013",
month = "5",
day = "27",
doi = "10.1097/TP.0b013e31827fac48",
language = "English",
volume = "95",
pages = "791--800",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Sorafenib induces autophagy in human myeloid dendritic cells and prolongs survival of skin allografts

AU - Lin, Jiunn Chang

AU - Huang, Wei Pang

AU - Liu, Chien Liang

AU - Lee, Jie Jen

AU - Liu, Tsang Pai

AU - Ko, Wen Chin

AU - Huang, Yu Chuen

AU - Hsu, Ming Ling

AU - Wu, Chih Hsiung

AU - Chen, Yu Jen

PY - 2013/5/27

Y1 - 2013/5/27

N2 - Background. Sorafenib, a multikinase inhibitor approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, has been reported inhibitory on the function of dendritic cells. This study was aimed to determine the effects of sorafenib on inducing autophagy and immunomodulatory activity and its implication on graft rejection. Methods. Cell viability and surface antigens were examined by 7-amino-actinomycin D and flow cytometric analysis. Autophagy was characterized using light microscopy and transmission electron microscopy for morphology, Western blotting for LC3B-I lipidation and mammalian target of rapamycin signaling molecules, and immunofluorescence staining for endogenous LC3B, GFP-LC3 transfection, and acidic component vacuoles. Skin allograft in mice was used as an experimental transplantation rejection model. Soluble factors contained in culture medium and serum were measured by enzyme-linked immunosorbent assay. Results. We found that sorafenib inhibited the viability of dendritic cells accompanied by morphologic changes characteristic of autophagy and immature differentiation. This autophagic effect induced by sorafenib was validated by LC3B-I lipidation and autophagosome accumulation. Sorafenib treatment was associated with the down-regulation of phosphorylated mammalian target of rapamycin and its downstream substrate p70S6K. We next performed skin graft model to testify the role of sorafenib-induced immature and autophagic dendritic cells. Intriguingly, sorafenib prolonged the survival of skin allograft without major toxicity. Blockade of autophagic flux by chloroquine partially diminished the protective effect of sorafenib, indicating an autophagy-related mechanism in vivo. Conclusion. This study suggests that sorafenib, in addition to being an anticancer agent, may have potential to be developed as a new category of immunosuppressant drugs acting via autophagy induction of dendritic cells.

AB - Background. Sorafenib, a multikinase inhibitor approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, has been reported inhibitory on the function of dendritic cells. This study was aimed to determine the effects of sorafenib on inducing autophagy and immunomodulatory activity and its implication on graft rejection. Methods. Cell viability and surface antigens were examined by 7-amino-actinomycin D and flow cytometric analysis. Autophagy was characterized using light microscopy and transmission electron microscopy for morphology, Western blotting for LC3B-I lipidation and mammalian target of rapamycin signaling molecules, and immunofluorescence staining for endogenous LC3B, GFP-LC3 transfection, and acidic component vacuoles. Skin allograft in mice was used as an experimental transplantation rejection model. Soluble factors contained in culture medium and serum were measured by enzyme-linked immunosorbent assay. Results. We found that sorafenib inhibited the viability of dendritic cells accompanied by morphologic changes characteristic of autophagy and immature differentiation. This autophagic effect induced by sorafenib was validated by LC3B-I lipidation and autophagosome accumulation. Sorafenib treatment was associated with the down-regulation of phosphorylated mammalian target of rapamycin and its downstream substrate p70S6K. We next performed skin graft model to testify the role of sorafenib-induced immature and autophagic dendritic cells. Intriguingly, sorafenib prolonged the survival of skin allograft without major toxicity. Blockade of autophagic flux by chloroquine partially diminished the protective effect of sorafenib, indicating an autophagy-related mechanism in vivo. Conclusion. This study suggests that sorafenib, in addition to being an anticancer agent, may have potential to be developed as a new category of immunosuppressant drugs acting via autophagy induction of dendritic cells.

KW - Allograft tolerance

KW - Autophagy

KW - Dendritic cell

KW - mTOR

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84877604813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877604813&partnerID=8YFLogxK

U2 - 10.1097/TP.0b013e31827fac48

DO - 10.1097/TP.0b013e31827fac48

M3 - Article

C2 - 23354299

AN - SCOPUS:84877604813

VL - 95

SP - 791

EP - 800

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 6

ER -